1330064-75-9

Basic information

• Product Name: C₁₃H₁₀ClN₃
• CAS NO: 1330064-75-9
• Molecular Weight: 243.695
• Mol File: 1330064-75-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: C₁₃H₁₀ClN₃(CAS DataBase Reference)
• NIST Chemistry Reference: C₁₃H₁₀ClN₃(1330064-75-9)
• EPA Substance Registry System: C₁₃H₁₀ClN₃(1330064-75-9)

Safety Data

• Hazardous Substances Data: 1330064-75-9(Hazardous Substances Data)

Upstream product

• 350-46-9 4-Fluoronitrobenzene 
• 1330064-83-9 C₁₃H₈ClN₃O₂ 
• 13096-96-3 4-chloro-1H-indazole 

Downstream Products

• 1330064-50-0 C₂₁H₁₃Cl₂F₃N₄O 
• 1330064-61-3 C₂₁H₁₄ClF₃N₄O 

Relevant articles and documents

Synthesis of indazole based diarylurea derivatives and their antiproliferative activity against tumor cell lines

New series of indazole based diarylureas were synthesized and their anticancer activity against cancer cells H460, A549, OS-RC-2, HT-29, Lovo, HepG2, Bel-7402, SGC-7901 and MDA-MB-231 were examined. These derivatives of diarylureas, except azaindazole based diarylureas 5f, 5l and 5m, showed superior or similar activity against most of these selected cancer cell lines to the reference compound sorafenib. The effect of substituents on the indazole ring was also investigated. Derivatives with trifluoromenthy or halogen substituent on the indazole ring showed higher activity against the selected cancer cell lines than sorafenib. The acute toxicity assay showed that compounds 5a, 5b and 5i possessed lower toxicity than sorafenib. Compound 5i with 4-(trifluoromenthy)-1H-indazole and 4-(trifluoromenthy) benzene moieties exhibited the most potent anticancer activity.